Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2616-2626

  Mozdzanowska, Krystyna ^a   Feng, JinQi ^a   Eid, Mark ^a   Kragol, Goran ^a   Cudic, Mare ^a   Otvos Jr , Laszlo ^a   Gerhard, Walter ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Influenza; M2; Vaccination

Indexed keywords

MATRIX PROTEIN 2; MULTIPLE ANTIGEN PEPTIDE VACCINE; PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNE SYSTEM; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; TRACHEA; VACCINATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0038402706     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00040-9     Document Type: Article

References (49)

1. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 13:1995;1399-1402.
2. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 17:1999;2237-2244.
3. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., MinJou W., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1999;1157-1163.
4. Okuda K., Ihata A., Watabe S.et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine. 19:2001;3681-3691.
5. Lamb R.A., Lai C.-J., Choppin P.W. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc. Natl. Acad. Sci. U.S.A. 78:1981;4170-4174.
6. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell. 40:1985;627-633.
7. Holsinger L.J., Lamb R.A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology. 183:1991;32-43.
8. Sugrue R.J., Hay A.J. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology. 180:1991;617-624.
9. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62:1988;2762-2772.
10. Steinhauer D.A., Wharton S.A., Skehel J.J., Wiley D.C., Hay A.J. Amantadine selection of a mutant influenza virus containing an acid-stable haemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. Proc. Natl. Acad. Sci. U.S.A. 88:1991;11525-11529.
11. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell. 69:1992;517-528.
12. Zhirnov O.P. Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses. Virology. 176:1990;274-279.
13. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 65:1991;5491-5498.
14. Hughey P.G., Roberts P.C., Holsinger L.J., Zebedee S.L., Lamb R.A., Compans R.W. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Virology. 212:1995;411-421.
15. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1990;1375-1377.
16. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with non-neutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology. 254:1999;138-146.
17. Epstein S.L., Misplon J.A., Lawson C.M., Subbarao E.K., Connors M., Murphy B.R. B2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J. Immunol. 150:1993;5484-5493.
18. Jakeman K.J., Smith H., Sweet C. Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. J. Gen. Virol. 70:1989;1523-1531.
19. Kragol G., Otvos L. Orthogonal solid-phase synthesis of tetramanosylated peptide constructs carrying three independent branched epitopes. Tetrahedron. 57:2001;957-966.
20. Kragol G., Otvos L., Geng J.Q., Gerhard W., Wade J. Synthesis of a disulfide-linked octameric peptide construct carrying three different antigenic determinants. Bioorg. Med. Chem. Lett. 11:2001;1417-1420.
21. Fields G.B., Noble R.L. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35:1990;161-214.
22. Brand C.M., Skehel J.J. Crystalline antigen from influenza virus envelope. Nature (Lond). 238:1972;145-147.
23. Kilbourne E.D. Future influenza vaccines and use of genetic recombinants. Bull. WHO. 41:1969;643-645.
24. + T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology. 239:1997;217-225.
25. Krieg A.M., Yi A.-K., Matson S.et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
26. Yi A.-K., Tuetken R., Redford T., Waldschmidt M., Kirsch J., Krieg A.M. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160:1998;4755-4761.
27. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine. 18:2000;231-237.
28. Gerhard W., Haberman A.M., Scherle P.A., Taylor A.H., Palladino G., Caton A.J. Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34(H1N1) which are recognized by class II-restricted T cells from BALB/c mice. J. Virol. 65:1991;364-372.
29. Engering A.J., Cella M., Fluitsma D.et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27:1997;2417-2425.
30. Tan M.C.A.A., Mommaas A.M., Drijfgout J.W.et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 27:1997;2426-2435.
31. Keil W., Geyer R., Dabrowski J.et al. Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional H n.m.r. and methylation. EMBO J. 4:1985;2711-2720.
32. Sette A., Buus S., Colon S., Miles C., Grey H.M. Structural analysis of peptides capable of binding to more than one Ia antigen. J. Immunol. 142:1989;35-40.
33. d-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity. 8:1998;319-329.
34. Engelhard V.H. Structure of peptides associated with MHC class I molecules. Curr. Opin. Immunol. 6:1994;13-23.
35. d exploits a four residue peptide binding motif. J. Exp. Med. 178:1993;1877-1892.
36. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:1997;235-270.
37. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1994;1653-1661.
38. Tamura S., Miyata K., Matsuo K. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156:1996;3892-3900.
39. + T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72:1998;6548-6553.
40. + T cells can promote survival and recovery after challenge. Int. Immunol. 12:2000;91-101.
41. Persson C.G.A., Erjefalt J.S., Greiff L.et al. Contribution of plasma-derived molecules to mucosal immune defense. Scand. J. Immunol. 47:1998;302-313.
42. Jones P.D., Ada G.L. Persistence of influenza virus-specific antibody-secreting cells and B-cell memory after primary murine influenza virus infection. Cell Immunol. 109:1987;53-64.
43. Bice D.E., Shopp G.M. Antibody responses after lung immunization. Exp. Lung Res. 14:1988;133-155.
44. Tamura S., Iwasaki T., Thompson A.H.et al. Antibody-forming cells in thenasal-associated lymphoid tissue during primary influenza virus infection. J. Gen. Virol. 79:1998;291-299.
45. Liang B., Hyland L., Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J. Virol. 75:2001;5416-5420.
46. Yilma T., Zee Y.C., Osebold J.W. Immunofluorescence determination of the pathogenesis of infection with influenza virus in mice following exposure to aerosolized virus. J. Inf. Dis. 139:1979;458-464.
47. Black R.A., Rota P.A., Gorodkova N., Klenk H.-D., Kendal A.P. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74:1993;143-146.
48. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 72:1998;8682-8689.
49. Gianfrani C., Oseroff C., Sidney J., Chestnut R.W., Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 61:2000;438-452.